Highlights
In this single-center quality-improvement study, implementation of a clinical care guideline for nebulized tranexamic acid (TXA) in post-tonsillectomy hemorrhage (PTH) was associated with rapid uptake and high adherence, supported by a dedicated emergency department order set.
Among patients presenting with active bleeding or visible clot who met protocol criteria, 81.3% were eligible for TXA, and the order set was used in 95.7% of emergency department cases receiving treatment.
The proportion of patients requiring operative control of PTH fell from 50.0% before implementation to 27.1% after implementation, an absolute risk reduction of 0.320 (95% CI 0.116-0.500; p = 0.001).
The study illustrates how structured implementation science, rather than pharmacology alone, may determine whether a promising therapy becomes reliable bedside practice.
Background
Post-tonsillectomy hemorrhage remains one of the most consequential complications after tonsillectomy. Although most episodes are self-limited, bleeding can be clinically significant, logistically disruptive, and occasionally life-threatening because the oropharynx is not easily compressible and airway compromise may develop rapidly. PTH also carries a substantial systems burden: unplanned emergency department visits, otolaryngology consultation, potential hospital admission, repeated anesthesia exposure, and return to the operating room.
Management of PTH varies according to bleeding severity, timing, patient age, and institutional culture. Traditional care has often emphasized observation, suctioning of clot, IV access, laboratory evaluation when indicated, urgent otolaryngology involvement, and operative control for persistent or concerning bleeding. In recent years, topical and nebulized tranexamic acid have emerged as attractive adjuncts because they are relatively easy to administer, mechanistically plausible, and generally familiar across other bleeding settings.
Tranexamic acid is an antifibrinolytic agent that inhibits the conversion of plasminogen to plasmin, thereby stabilizing fibrin clot. Its role is well established in trauma, surgery, postpartum hemorrhage, and some mucosal bleeding scenarios. Interest in nebulized TXA has grown because local delivery may achieve hemostatic benefit while avoiding some of the complexity of systemic administration. For PTH in particular, nebulization offers practical advantages in the emergency department, especially when cooperation is limited and direct topical application is difficult.
Yet adoption of new interventions in hospital practice is rarely straightforward. Staff turnover, workflow variability, uncertainty about indications, and formulary or prescribing friction commonly limit implementation. The study by Lavin and colleagues is therefore notable not only for evaluating nebulized TXA, but for studying a clinical care guideline designed to make its use reliable in real-world emergency care.
Study Design and Intervention
Lavin J, Billings K, Smith A, Patel K, Corboy J, and Hazkani I reported a quality-improvement initiative using Model for Improvement methodology to develop and implement a clinical care guideline for nebulized TXA in PTH. The study compared outcomes during two time periods: the 2 years before implementation and the 2 years after implementation.
The target population consisted of patients presenting to the emergency department with post-tonsillectomy bleeding. The guideline defined eligibility for nebulized TXA as the presence of active bleeding or a visible blood clot. Patients meeting criteria were to receive three nebulized TXA treatments. Exclusion criteria included severe bleeding, absence of active bleeding or clot, inability to tolerate treatment, or inability to protect the airway. These exclusions are clinically sensible because severe hemorrhage or an unstable airway should prompt expedited operative and airway-focused management rather than reliance on a temporizing nebulized therapy.
To support uptake, the team embedded the protocol in an emergency department order set. This implementation choice is highly relevant. Order sets translate policy into action by reducing reliance on memory, standardizing dose delivery, and signaling shared ownership between emergency medicine, nursing, pharmacy, and otolaryngology.
The study’s measured outcomes included emergency department returns for PTH, frequency of order set use, frequency of TXA administration, return to the operating room for hemorrhage control, and secondary returns to the emergency department. Although the report primarily highlights effectiveness and implementation metrics, the design should be understood as a before-and-after observational quality-improvement study rather than a randomized controlled trial.
Patient Volume and Eligibility
Across the study periods, there were 2,805 tonsillectomies before guideline implementation and 5,382 after implementation. Despite this increase in procedural volume, the rate of emergency department return for bleeding did not differ significantly between eras: 70 cases pre-implementation (2.5%) versus 155 cases post-implementation (2.9%), with p > 0.05. This finding is important because it suggests the observed reduction in operative intervention was not simply explained by a lower underlying rate of bleeding presentations in the post-implementation period.
There was no difference in patient age between groups, which provides at least some reassurance regarding comparability of case mix. After implementation, 126 of 155 patients presenting with PTH met inclusion criteria for TXA, corresponding to 81.3%. This proportion indicates that the protocol was applicable to a large majority of emergency presentations, while still preserving clinical discretion for patients with severe bleeding or airway concerns.
Key Results
The implementation outcomes were striking. Among patients receiving TXA in the emergency department, the order set was used in 95.7% of cases, suggesting excellent integration into routine workflow. High order-set adoption matters because guideline failure in everyday practice often stems from process failure rather than lack of therapeutic efficacy.
The most clinically consequential outcome was operative management of PTH. Before implementation, 35 of 70 patients with emergency department presentations for bleeding required operative control, a rate of 50.0%. After implementation, 42 of 155 patients returned to the operating room, a rate of 27.1%. This difference was statistically significant (p = 0.001) and corresponded to an absolute risk reduction of 0.320, with a 95% confidence interval of 0.116 to 0.500.
From a clinical standpoint, this effect size is meaningful. If the association reflects a true causal benefit, fewer patients required repeat anesthesia, surgical intervention, perioperative resource utilization, and inpatient recovery. This would be relevant not only for patient safety and family burden, but also for operating-room capacity and hospital throughput.
The abstract does not provide a full breakdown of secondary emergency department returns or detailed safety events, and that limits granular interpretation. Still, the absence of a signal in the abstract suggesting worsened re-presentation is somewhat reassuring. For any nonoperative bleeding strategy, one key concern is whether apparent short-term control merely delays definitive treatment. More complete reporting in the full article will be important to determine whether delayed operative interventions or repeated visits offset some of the observed benefit.
Clinical Interpretation
This study supports two linked conclusions. First, nebulized TXA can be operationalized successfully for selected patients with PTH in a busy emergency setting. Second, a carefully designed clinical care guideline may be as important as the drug itself in achieving measurable benefit.
The biological rationale for TXA in mucosal bleeding is strong. Post-tonsillectomy wounds are fibrinolytically active, and clot instability is a plausible contributor to recurrent bleeding. Delivering antifibrinolytic therapy directly to the oropharynx by nebulization may help stabilize clot at the operative bed without requiring vascular access or oral cooperation. In practical terms, this makes TXA an attractive early intervention while otolaryngology evaluation is underway.
At the same time, clinicians should resist overgeneralization. The protocol was not intended for severe hemorrhage or for patients unable to protect the airway. These are precisely the scenarios in which delayed escalation would be most dangerous. The study therefore supports nebulized TXA as a structured adjunct for selected, non-exsanguinating PTH rather than a replacement for airway vigilance or timely operative control.
The implementation framework is also instructive. The team used Model for Improvement methodology, developed explicit inclusion and exclusion criteria, and embedded the protocol into an order set. This combination addresses several well-known barriers to adoption: ambiguity about eligibility, treatment inconsistency across rotating staff, and delays caused by ad hoc ordering. Hospitals considering similar pathways should note that the success reported here likely depended on this systems design.
Strengths of the Study
A major strength is its real-world focus. Rather than examining TXA under highly controlled experimental conditions, the investigators assessed whether a hospital could implement a practical protocol and whether that protocol was associated with meaningful patient-centered and system-level outcomes. This type of work is highly relevant to clinicians who must decide not only whether a therapy can work, but whether it can work reliably in ordinary practice.
The study also included a substantial number of tonsillectomies across both periods and assessed a hard clinical endpoint: return to the operating room. Operative intervention is more robust than softer outcomes such as subjective improvement in bleeding. The reported absolute risk reduction and confidence interval further strengthen interpretability.
Another strength is the clearly defined treatment algorithm. Restricting TXA to patients with active bleeding or visible clot improves face validity, while excluding severe bleeding and compromised airway situations aligns the protocol with patient safety.
Limitations and Cautions
The principal limitation is the nonrandomized before-and-after design. Secular changes in practice, referral patterns, staffing, surgical technique, threshold for operative intervention, or other unmeasured confounders could have influenced the observed reduction in OR returns. Because the post-implementation period also included more total tonsillectomies and more bleeding presentations, there may have been shifts in case identification or institutional workflow that are not captured by the abstract.
Selection bias is another concern. Clinicians may have preferentially reserved operative management for more severe cases and used TXA in those appearing more stable. Although the guideline attempted to standardize this distinction, clinical judgment remains unavoidable in PTH. This makes causal attribution to nebulized TXA alone uncertain.
The abstract also provides limited safety data. Nebulized TXA is generally considered well tolerated, but adverse events such as bronchospasm, poor tolerance, aspiration risk in actively bleeding patients, or false reassurance leading to delayed definitive management are important to examine. Full-text details will be needed before drawing strong safety conclusions.
Generalizability may also be limited. Institutions differ in emergency department staffing, pharmacy support, ENT availability, and baseline thresholds for taking patients to the OR. The effectiveness of the guideline may therefore depend on local context, especially where otolaryngology coverage is less immediate or where nebulized TXA is not already familiar to emergency clinicians.
Relation to Existing Literature
The findings are consistent with a broader trend in the literature supporting topical or nebulized TXA for upper airway and mucosal bleeding, though high-quality randomized data in PTH remain limited. Prior case reports and small series have suggested that nebulized TXA may reduce active bleeding and stabilize patients before definitive management. What distinguishes the present report is its focus on implementation and its association with reduced operative intervention at the institutional level.
This quality-improvement emphasis fills an important gap. In many hospitals, promising interventions fail because they are not embedded into workflows. By demonstrating high order-set use and high protocol adherence, the study contributes not only to the hemostasis literature but also to implementation science in acute care otolaryngology.
Implications for Clinical Practice
For emergency physicians, otolaryngologists, pediatricians, nurses, and pharmacists, the study suggests that nebulized TXA can be incorporated into a standardized PTH pathway for selected patients. A reasonable operational approach, based on the reported protocol, is early identification of patients with active bleeding or visible clot, rapid assessment of airway safety, prompt ENT consultation, and immediate initiation of nebulized TXA when exclusion criteria are absent.
For hospital leaders, the practical lesson is that protocol design matters. A successful pathway likely requires formulary readiness, nursing education, prebuilt order sets, shared escalation criteria, and explicit instructions for when nebulized treatment is not appropriate. Without these supports, adoption may become inconsistent, especially in settings with frequent trainee turnover.
Importantly, nebulized TXA should not be framed as a reason to relax vigilance. Post-tonsillectomy bleeding remains an airway-sensitive emergency. Continuous reassessment, suction as needed, positioning to minimize aspiration, NPO status, and readiness for rapid operative intervention remain central to care.
Research Priorities
The next steps should include prospective multicenter studies to test whether the observed reduction in operative management is reproducible across institutions. Randomized or pragmatic cluster-randomized designs would help distinguish the effect of TXA from the effect of protocolization itself. Future reports should also define optimal dose, frequency, timing relative to bleeding onset, durability of hemostasis, and patient subgroups most likely to benefit.
Safety deserves more detailed evaluation, particularly in younger children, patients with brisk bleeding, and those with reactive airway disease. Cost-effectiveness analysis would also be valuable, since even a modest decrease in return to the operating room could translate into meaningful resource savings if safety is maintained.
Funding and Trial Registration
The abstract provided does not report funding information or a ClinicalTrials.gov registration number. Given the quality-improvement design, formal trial registration may not have been applicable, but readers should consult the final published article for full disclosures and institutional review details.
Conclusion
The study by Lavin and colleagues provides persuasive early evidence that a clinical care guideline for nebulized TXA in post-tonsillectomy hemorrhage can be implemented with high fidelity and may substantially reduce return to the operating room. The reported drop in operative management from 50.0% to 27.1% is clinically important, although the nonrandomized design precludes firm causal inference.
For clinicians, the message is practical: nebulized TXA appears to be a useful adjunct for selected patients with PTH, particularly when integrated into a clear emergency department algorithm with explicit airway and severity exclusions. For health systems, the study is a reminder that implementation strategy can determine whether evidence-informed therapies actually improve outcomes. Further multicenter prospective research is needed, but this report offers a credible model for translating a promising intervention into standardized acute care practice.
Citation
Lavin J, Billings K, Smith A, Patel K, Corboy J, Hazkani I. Clinical Care Guideline Implementation of Nebulized Tranexamic Acid in Post-Tonsillectomy Hemorrhage. Laryngoscope. 2026 May 29. doi: 10.1002/lary.70641. Epub ahead of print. PMID: 42212485.
